CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Bristol Myers Squibb›
News
Bristol Myers Squibb

Bristol Myers Squibb

Leading American pharmaceutical company specializing in research and development.

Operating headquarters
New York City, NY, US🇺🇸
Founded
1887
Loading
Overview
M & A
Analysis
Compare
Fundraising
Employees
News
Library

Latest News About Bristol Myers Squibb

Bristol Myers Squibb to report third-quarter 2026 results on October 29

Bristol Myers Squibb

Bristol Myers Squibb to report third-quarter 2026 results on October 29

The company scheduled its third-quarter 2026 results announcement for late October.

Sep 18, 2026

Bristol Myers Squibb Presents Sotyktu deucravacitinib Two-Year Data in Adults with Psoriatic Arthritis

Bristol Myers Squibb

Bristol Myers Squibb Presents Sotyktu deucravacitinib Two-Year Data in Adults with Psoriatic Arthritis

New two-year POETYK PsA-2 results showed durable efficacy and consistent safety for the Sotyktu therapy in adults with psoriatic arthritis.

Sep 17, 2026

Bristol Myers Squibb receives accelerated FDA approval for Zenbexus combination in relapsed multiple myeloma

Bristol Myers Squibb

Bristol Myers Squibb receives accelerated FDA approval for Zenbexus combination in relapsed multiple myeloma

FDA granted accelerated approval to the Zenbexus triple combination for multiple myeloma patients as early as first relapse.

Aug 13, 2026

Bristol Myers Squibb Announces Opdivo nivolumab in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma

Bristol Myers Squibb

Bristol Myers Squibb Announces Opdivo nivolumab in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma

BMS announced Opdivo in combination with AVD received an expanded EU label with approval in frontline advanced classical Hodgkin lymphoma.

Jun 1, 2026

European Commission Approves Sotyktu deucravacitinib for Active Psoriatic Arthritis in Adults

Bristol Myers Squibb

European Commission Approves Sotyktu deucravacitinib for Active Psoriatic Arthritis in Adults

European regulators cleared Sotyktu for adults with active psoriatic arthritis, extending the product reach in Europe.

May 8, 2026

BMS brings the buzz around late-stage readouts amid a solid Q1

Pharmaceutical Technology

BMS brings the buzz around late-stage readouts amid a solid Q1

Pharmaceutical Technology reports BMS Q1 2026 results with Cobenfy at $56M quarterly revenue and upcoming ADEPT Alzheimer's psychosis...

May 1, 2026